SciELO - Scientific Electronic Library Online

vol.37 número5Daño renal agudo secundario a diarrea debido a enteropatía “sprue-like” asociada al olmesartanNiveles no-críticos de excreción urinaria de cadmio como factor de riesgo asociado con marcadores tubulares de daño renal temprano en la región central de México índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Nefrología (Madrid)

versión On-line ISSN 1989-2284versión impresa ISSN 0211-6995

Nefrología (Madr.) vol.37 no.5 Cantabria sep./oct. 2017 

Letters to the Editor

Switch to belatacept in kidney graft recipients

Cambio a belatacept en trasplante renal

María O. López-Olivaa  , Laura Álvareza  , Mª Luisa Testillanob  , Tamara Pérezb  , María Fernández Nietoa  , Mª José Santanaa  , Elena Gonzáleza  , Alicia Herrerob  , Rafael Selgasa  , Carlos Jiméneza 

aNephrology Department, University Hospital La Paz, Madrid, Spain

bPharmacy Department, University Hospital La Paz, Madrid, Spain

Dear editor:

Calcineurin inhibitors (CNIs) are the gold standard immunosuppression in kidney transplant recipients. These drugs have shown better results in graft survival and patient outcome during the first year after transplantation. However, long-term use is associated with acute and chronic nephrotoxicity, which predisposes to graft loss.

Belatacept is a fusion protein binding to CD80 or CD86 ligands on antigen presenting cells that selectively blocks T-cell costimulatory signals. Data derived from two phase III trials (BENEFIT and BENEFIT-EXT) demonstrated the efficacy and safety of Belatacept in combination with Basiliximab, steroids and mycophenolic acid preventing graft acute rejection in Epstein-Barr virus positive recipients. Recently, the results of BENEFIT and BENEFIT-EXT study after 7 year follow up confirmed former data and showed a significant reduction in death and graft loss associated with the use of belatacept.1

Given the relevance of its beneficial effects in kidney function, some authors have proposed switching CNIs into belatacept treatment in intolerant patients to calcineurin or mTOR inhibitors showing an improvement in renal function.2-5

In our country, the administration of Belatacept is restricted by public health insurance. Public hospitals may use belatacept after individualized assessment requiring specific approval by internal committees in each case.

We summarize (Table 1) our clinical experience of switching to belatacept in 5 kidney transplant recipients through 2013-2015 after failure or intolerant therapy to tacrolimus and/or everolimus. All patients were Epstein-Barr virus positive.

Table 1 Description clinical cases. 

ECD, expanded criteria donor; DCD, donor after circulatory death; ARF, Acute renal failure; IS, immunosuppression; Tx, transplantation; TMA, thrombotic microangiopathy; CNI, calcineurin inhibitors; HTN, arterial hypertension; ATN, acute tubular necrosis; IFTA, interstitial fibrosis and tubular atrophy; Tacro, Tacrolimus; Cyclo, Cyclosporine; Ever, Everolimus; MMF, mycophenolate mofetil; NA, not available.

Pre-transplant kidney biopsies were not performed. Clinical data were compatible with suboptimal donors, predisposing to a recipient poorer renal function. After transplantation patients received immunosuppression therapy consisting of anti-lymphocyte depleting antibodies, steroids and mycophenolic acid postponing tacrolimus starting to minimize delayed graft function. In four patients (cases 2, 3, 4 and 5) renal function was not adequate in the first month post-transplant. Analysis of graft biopsy showed CNI toxicity and chronic vascular lesions (likely related with donor background), but no evidence of acute rejection. Everolimus was considered an alternative to tacrolimus in all four cases. However it was not tolerated because of proteinuria or bone pain. In case 1 the reason for graft dysfunction was a thrombotic microangiopathy (TMA) due to the sequential use of tacrolimus first and cyclosporine later. They were converted to belatacept between 2 and 8 months post-transplantation showing immediate improvement of kidney function. Furthermore, anti HLA antibodies were negative after one year post-conversion.

Patients with low immunological risk (cases 1, 3, 4 and 5) received belatacept at a less intense dosage5 and in case 2 the dosage of belatacept was more intense5 due to positive class I anti-HLA antibodies (no donor specific antibodies).

All together, switching to belatacept is effective and safe in patients with failure therapy and/or intolerant to calcineurin or mTOR inhibitors at distinct time periods since transplantation. Moreover, belatacept was associated with better kidney function with no adverse events at short term and is an excellent alternative in grafts with renal dysfunction due to chronic vascular lesions or to CNI-TMA. This positive experience requires long-term assessments to confirm improvement in graft outcome.


1. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333-43. [ Links ]

2. Paz M, Roberti J, Mos F, Cicora F. Conversion to belatacept-based immunosuppression therapy in renal transplant patients. Transplant Proc. 2014;46:2987-90. [ Links ]

3. Gupta G, Regmi A, Kumar D, Posner S, Posner MP, Sharma A, et al. Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction. Am J Transpl. 2015;15:2726-31. [ Links ]

4. Le Meur Y, Aulagnon F, Bertrand D, Heng AE, Lavaud S, Caillard S, et al. Effect of an early switch to belatacept among CNI-intolerant graft recipients of kidneys from extended criteria donors. Am J Transpl. 2016;16:2181-6. [ Links ]

5. Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, Del Carmen Rial M, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011;6:430-9. [ Links ]

Corresponding author. E-mail address: (M.O. López-Oliva).

Conflict of interest

The authors declare that they have no conflicts of interest.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License